Imiquimod Enhances IFN-γ Production and Effector Function of T Cells Infiltrating Human Squamous Cell Carcinomas of the Skin

作者: Susan J. Huang , Dirkjan Hijnen , George F. Murphy , Thomas S. Kupper , Adam W. Calarese

DOI: 10.1038/JID.2009.151

关键词:

摘要: Squamous cell carcinomas (SCCs) are sun-induced skin cancers that particularly numerous and aggressive in patients taking T-cell immunosuppressant medications. Imiquimod is a topical immune response modifier Toll-like receptor 7 (TLR7) agonist induces the immunological destruction of SCC other cancers. TLR7 activation by imiquimod has pleiotropic effects on innate cells, but its T cells remain largely uncharacterized. Because tumor formation memory ultimately T-cell-mediated effects, we studied therapy effector infiltrating human SCC. treated with before excision contained dense infiltrates associated apoptosis histological evidence regression. Effector from produced more IFN-γ, granzyme, perforin less IL-10 transforming growth factor-β (TGF-β) than untreated tumors. Treatment normal induced resident reduced production had no effect perforin, or suggesting these latter arise recruitment distinct populations into Thus, stimulates recruiting cutaneous blood inhibiting tonic anti-inflammatory signals within tumor.

参考文章(44)
Keith B. Gorden, Kevin S. Gorski, Sheila J. Gibson, Ross M. Kedl, William C. Kieper, Xiaohong Qiu, Mark A. Tomai, Sefik S. Alkan, John P. Vasilakos, Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. Journal of Immunology. ,vol. 174, pp. 1259- 1268 ,(2005) , 10.4049/JIMMUNOL.174.3.1259
Shimon Sakaguchi, Noriko Sakaguchi, Misako Itoh, Masanao Asano, Masaaki Toda, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology. ,vol. 155, pp. 1151- 1164 ,(1995)
AW Macfarlane, MG Lord, M Konstantopoulou, Treatment of invasive squamous cell carcinoma with 5-percent imiquimod cream. Dermatology Online Journal. ,vol. 12, pp. 10- ,(2006)
Monica C Panelli, Mitchell E Stashower, Herbert B Slade, Kina Smith, Christopher Norwood, Andrea Abati, Patricia Fetsch, Armando Filie, Shelley-Ann Walters, Calvin Astry, Eleonora Aricó, Yingdong Zhao, Silvia Selleri, Ena Wang, Francesco M Marincola, Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection Genome Biology. ,vol. 8, pp. 1- 15 ,(2007) , 10.1186/GB-2007-8-1-R8
S M Dubinett, B J Nickoloff, K Uyemura, R L Modlin, J Kim, T McHugh, R L Moy, IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. Journal of Immunology. ,vol. 155, pp. 2240- 2247 ,(1995)
Sheila J Gibson, Jana M Lindh, Tony R Riter, Raymond M Gleason, Lisa M Rogers, Ashley E Fuller, JoAnn L Oesterich, Keith B Gorden, Xiaohong Qiu, Scott W McKane, Randy J Noelle, Richard L Miller, Ross M Kedl, Patricia Fitzgerald-Bocarsly, Mark A Tomai, John P Vasilakos, Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod Cellular Immunology. ,vol. 218, pp. 74- 86 ,(2002) , 10.1016/S0008-8749(02)00517-8
Hiroaki Hemmi, Tsuneyasu Kaisho, Osamu Takeuchi, Shintaro Sato, Hideki Sanjo, Katsuaki Hoshino, Takao Horiuchi, Hideyuki Tomizawa, Kiyoshi Takeda, Shizuo Akira, Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunology. ,vol. 3, pp. 196- 200 ,(2002) , 10.1038/NI758
J. Lee, T.-H. Chuang, V. Redecke, L. She, P. M. Pitha, D. A. Carson, E. Raz, H. B. Cottam, Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7 Proceedings of the National Academy of Sciences of the United States of America. ,vol. 100, pp. 6646- 6651 ,(2003) , 10.1073/PNAS.0631696100
SHEILA J. GIBSON, LINDA M. IMBERTSON, TAMARA L. WAGNER, TRACI L. TESTERMAN, MICHAEL J. REITER, RICHARD L. MILLER, MARK A. TOMAI, Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609 Journal of Interferon and Cytokine Research. ,vol. 15, pp. 537- 545 ,(1995) , 10.1089/JIR.1995.15.537